Narrative Dx #002: Healthcare's Chief AI Officer Problem Isn't a Hiring Problem
Welcome to Narrative Dx, my new series on Narrative Strategy for Healthcare. I'm performing story surgery on the healthcare industry — with an occasional tangent into life sciences and biotech. Let's dive in.
David Hardoon left his AI role at Standard Chartered after less than a year. Asked whether a Chief AI Officer title should even be permanent, he didn’t hedge. “Do we have a chief Excel officer?” he said. We don’t have a chief email officer either. So why this?
It’s a banking quote. Swap in half the pharma and medtech companies making headlines right now, and it still lands.
Over the past two years, legacy healthcare and life sciences companies have created a wave of brand-new AI-strategy titles — Chief AI Officer, Head of AI, Chief Strategy Officer for AI. One widely cited CEO survey found adoption of the role nearly tripled in about a year. At the same time, tenure in the seat is already being described as short. People are leaving almost as fast as the title gets created.
If you’re sitting in one of these seats right now, none of this is news to you. You already know the title sounds bigger than the authority that actually came with it.
Here’s the part nobody puts in the job description. The company hired you to translate between its old story and the new one — an AI capability bolted onto a device business, an acquired platform absorbed into a pipeline. That’s the technical mandate, and it’s usually spelled out clearly. What isn’t spelled out is the narrative mandate: the actual authority to decide what the company says about itself once the new thing stops matching the old one. Nobody hands you that. You either claim it fast, or the gap gets filled by default — by whichever story was already loudest in the building before you arrived.
Three versions of that gap playing out in healthcare right now:
Recursion / Exscientia. Billed in 2024 as a “symbolic consolidation” of two AI-drug-discovery companies. By 2025, multiple pipelines had been discontinued, with restructuring “for integration efficiency” still underway into this year. Two companies got merged into one press release before anyone had built the authority to say, with confidence, whose story the combined company was actually telling.
Grail. A company whose entire identity was the AI story — the flagship multi-cancer early-detection test — just missed its primary clinical trial endpoint. The CEO is retiring. When the entire company’s narrative rests on one result, there’s no fallback story and no one whose job it was to build one.
CareCloud. The most useful example, because it shows what claiming the gap actually looks like in practice. Rather than leaving one executive to absorb both stories with no clear mandate, leadership split the job: a Chief Strategy Officer owns the AI vision, the CEO owns “disciplined execution.” Two narrators, one company — but at least it’s explicit. The Chief Strategy Officer in that seat now has a defined lane to build authority in, instead of a title and a guess.
That’s the real reason these roles keep turning over, and it’s worth being honest about what it isn’t: it’s not that AI strategy is too technical for one person to hold, and it’s not usually that the person in the seat lacks the skill. It’s that the narrative authority the job actually requires doesn’t ship with the title. The executives who hold onto these roles longest aren’t necessarily the ones with the cleanest technical credentials. They’re the ones who treat building that authority — deciding what the company says about itself, and getting the rest of the org to say it too — as the real job, not a side effect of the org chart. Most job descriptions don’t say that part out loud. It’s still the part that determines whether you’re still in the seat next year.
I'm Ari Mostov — I help healthtech and medtech leaders build the narrative authority that doesn't come standard with the title. More soon in this series, Narrative Dx.